Accent Microcell Past Earnings Performance
Past criteria checks 4/6
Accent Microcell has been growing earnings at an average annual rate of 120.8%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 23.2% per year. Accent Microcell's return on equity is 29.4%, and it has net margins of 6.4%.
Key information
120.8%
Earnings growth rate
120.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 23.2% |
| Return on equity | 29.4% |
| Net Margin | 6.4% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Accent Microcell makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 2,042 | 130 | 97 | 0 |
| 31 Mar 22 | 1,657 | 59 | 77 | 0 |
| 31 Mar 21 | 1,334 | 48 | 70 | 0 |
| 31 Mar 20 | 1,315 | 42 | 100 | 0 |
| 31 Mar 19 | 1,140 | 36 | 85 | 0 |
| 31 Mar 18 | 953 | 18 | 40 | 0 |
Quality Earnings: ACCENTMIC has high quality earnings.
Growing Profit Margin: ACCENTMIC's current net profit margins (6.4%) are higher than last year (3.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ACCENTMIC's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare ACCENTMIC's past year earnings growth to its 5-year average.
Earnings vs Industry: ACCENTMIC earnings growth over the past year (120.8%) exceeded the Pharmaceuticals industry 23.3%.
Return on Equity
High ROE: ACCENTMIC's Return on Equity (29.4%) is considered high.